BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2024 Results Conference Call August 5, 2024 5:30 PM ET
Company Participants
Traci McCarty - Head of Investor Relations
Alexander Hardy - President and Chief Executive Officer
Hank Fuchs - President, Worldwide Research & Development
Brian Mueller - Executive Vice President, Chief Financial Officer
Cristin Hubbard - Executive Vice President, Chief Commercial Officer
Conference Call Participants
Phil Nadeau - TD Cowen
Salveen Richter - Goldman Sachs
Ellie Merle - UBS
Cory Kasimov - Evercore
Jessica Fye - JPMorgan
Paul Matteis - Stifel
Joseph Schwartz - Leerink Partners
Chris Raymond - Piper Sandler
Gena Wang - Barclays
Kostas Biliouris - BMO Capital Markets
Mohit Bansal - Wells Fargo
Olivia Brayer - Cantor Fitzgerald
Luca Issi - RBC Capital
Operator
Good afternoon, and welcome to the BioMarin Pharmaceuticals Second Quarter 2024 Conference Call. Please note that this call is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions]
I will now turn the call over to Traci McCarty, Head of Investor Relations. You may begin your conference.
Traci McCarty
Thank you, Operator, to remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic search and development.
Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K reports.
In addition, we will use non-GAAP financial measures as defined in Regulation G during the call today. These non-GAAP measures should not be considered in isolation from, as substitutes for or superior to financial measures prepared in accordance with U.S. GAAP, and you can find the related reconciliations to U.S. GAAP in the earnings release and earnings presentation, both of which are available in the Investor Relations section of our website.
On the call from BioMarin management today are Alexander Hardy, President and Chief Executive Officer; Hank Fuchs, President of Worldwide R&D; Brian Mueller, Executive Vice President, Chief Financial Officer; and Cristin Hubbard, Executive Vice President, Chief Commercial Officer.
I will now turn the call over to BioMarin's President and CEO, Alexander Hardy.